公司简介

江苏众红生物工程创药研究院有限公司(简称“众红生物”)是由常州千红生化制药股份有限公司(深交所上市代码:002550;简称:千红制药)和国家“千人计划”特聘专家领衔的国际联合研发团队2011年8月共同投资创建位于江苏省常州市国家级高新技术开发区的独立法人单位。是一家集创新的生物医药研发技术、先进的管理运作模式、和谐的企业文化理念为一体的创新研发型生物医药企业。众红生物2015年被人社部和全国博士后管委会批准设立国家博士后科研工作站,2017年获批国家高新技术企业。


众红生物、京森生物(控股子公司)和晶红生科(参股子公司),依托自身成熟技术平台的科研成果转化能力和产学研融合优势,依靠由一批国内外知名的生物医药专家组成的跨国研发团队的技术支撑,主要从事具有自主知识产权针对癌症、心脑血管、内分泌与过敏等为主要适应症的基因工程蛋白酶类、人源与人源化抗体类和长效修饰蛋白类等创新药物的研发与转化,食品安全与临床诊断试剂和生物医药新材料的应用开发、成果转化和产业化。截止到2018年8月,众红生物与其子公司已申请国内和国际发明专利一百多项,其中已获授权专利数十项。我们力争将众红生物和其子公司建成有良好经济效益、受同行尊重、具自身特色的现代生物医药综合研发机构和产学研融合集成基地。


ZonHonBio (ZonHon Biopharma Institute, Inc.) located in Changzhou National High-tech Development Zone was co-founded in August 2011 by QianHongBio (Changzhou Qianhong Biopharma Co., Ltd., SZSE: 002550) and an international research and development team led by a State Specially Recruited Expert. ZonHonBio aims to be an independent and innovative bio-pharmaceutical company with advanced biotechnology, progressive management model and congenial enterprise culture. ZonHonBio was approved to set up a postdoctoral programme by the Ministry of Human Resources and Social Security and the National Postdoctoral Management Committee in 2015. ZonHonBio was also awarded the title of National High-tech Enterprise in 2017.


Relying on mature technology platform with the transformation capability of scientific research achievements and the advantage of industry-university-research integration, ZonHonBio, GENSUNBIO and GENHONBIO, the holding and participating subsidiaries of ZonHonBio respectively, are mainly engaged in the research and development of innovative drugs such as genetically engineered proteases, human and humanized antibodies and modified long-acting protein medicines targeting for cancer, cardiovascular, endocrine and allergy diseases. We also engage in the application, industrialization and commercialization of food safety and clinical diagnostic reagents and biomedical materials. All the achievements made by our multinational research team composed of well-known biologists and pharmacists have proprietary intellectual property rights. As of August 2018, ZonHonBio and its subsidiaries have applied for more than 100 domestic and international patents, among which dozens have been granted. Our aim is to build a modern biomedical research and development institution as well as an integrated industry-university-research base that is financially successful, respected by peers, and has our own characteristics.